NR546 Psychopharmacology Final Exam (2026/2027)
Comprehensive Assessment
2026-2027 | Total Questions: 100 | 100% VERIFIED
Introduction
This comprehensive assessment measures the core knowledge required of advanced
nursing nursing candidates preparing for the NR546 Psychopharmacology final
examination. The assessment spans nine domains: Psychopharmacokinetics and
Pharmacodynamics; Neurotransmitter Systems and Receptor Targets; Antidepressant
Therapies; Antipsychotic Medications and Metabolic Monitoring; Anxiolytics and Hypnotics;
Mood Stabilizers; Psychostimulants and ADHD Management; Substance Use Disorder
Pharmacotherapy; and Special Populations. Each question tests a distinct sub-topic mapped
to the official NR546 blueprint, requiring applied professional judgment, receptor-level
reasoning, and safe prescribing decisions rather than simple recall. Mastery of this material
demonstrates readiness for academic progression and supports safe, evidence-based
advanced psychiatric nursing clinical execution.
Question 1. A psychiatric medication undergoes extensive first-pass metabolism. The
clinical consequence is that:
A. The drug bypasses the liver entirely when taken orally
B. Only a fraction of the oral dose reaches systemic circulation, often requiring higher
oral than parenteral doses
C. All of the dose reaches the bloodstream unchanged after oral administration
D. The drug must always be given rectally to work
Correct Answer: B — Only a fraction of the oral dose reaches systemic circulation,
often requiring higher oral than parenteral doses
Rationale: Portal circulation delivers oral drugs directly to hepatic enzymes, so first-
pass metabolism degrades a portion before it reaches the blood, raising oral dose
requirements. The drug does not bypass the liver orally, full bioavailability is false, and
rectal dosing is not a general rule.
Question 2. A client takes a new antidepressant with a half-life of 30 hours. Approximately
how long until steady-state plasma levels are reached?
A. About 5 to 7 days, since steady state requires roughly five half-lives
B. About 60 hours, since two half-lives suffice
C. About 30 minutes after the first dose
D. About 3 months regardless of half-life
Correct Answer: A — About 5 to 7 days, since steady state requires roughly five
half-lives
, Rationale: Steady state is achieved after approximately five half-lives, so five times 30
hours equals 150 hours, about six days. Two half-lives, minutes, and months all
misapply the steady-state rule.
Question 3. A client who smokes two packs daily takes a medication metabolized by
CYP1A2. After smoking cessation, the nurse anticipates that:
A. Plasma levels will rise as the loss of CYP1A2 induction slows metabolism, requiring
dose reduction
B. Plasma levels will fall because smoking protects the drug
C. No change in levels occurs since smoking affects only the lungs
D. The drug must be switched to a parenteral form immediately
Correct Answer: A — Plasma levels will rise as the loss of CYP1A2 induction slows
metabolism, requiring dose reduction
Rationale: Polycyclic aromatic hydrocarbons in smoke induce CYP1A2; cessation
removes the induction, slowing clearance and raising levels of drugs such as olanzapine,
clozapine, and theophylline. Smoking does not lower or ignore drug levels, and the route
is irrelevant.
Question 4. A client with CYP2D6 poor metabolizer genotype takes nortriptyline and
develops marked side effects at a standard dose. The best explanation is:
A. The client has developed a sudden allergy to the medication
B. Poor metabolizers clear drugs faster than extensive metabolizers
C. Genotype has no influence on medication response
D. Reduced enzyme activity slows clearance, so the drug and active metabolites
accumulate
Correct Answer: D — Reduced enzyme activity slows clearance, so the drug and
active metabolites accumulate
Rationale: CYP2D6 poor metabolizers lack efficient enzyme function, so tricyclics and
many psychotropics accumulate, raising toxicity risk at standard doses. Allergy, faster
clearance, and genotype irrelevance are incorrect.
Question 5. A full agonist at a receptor is best described as a drug that:
A. Binds the receptor and produces the maximal possible intrinsic response
B. Binds the receptor and produces a submaximal response even at full occupancy
C. Binds the receptor and blocks endogenous neurotransmitter action completely
D. Binds nowhere and has no receptor activity
Correct Answer: A — Binds the receptor and produces the maximal possible
intrinsic response
Rationale: Full agonists produce maximal signal transduction upon binding. Partial
agonists give a submaximal ceiling, antagonists block rather than activate, and receptor-
less drugs describe nothing.
, Question 6. Classic antihistamines such as diphenhydramine act at the histamine receptor
as:
A. Full agonists, maximally stimulating histamine receptors
B. Partial agonists with ceiling effects
C. Inverse agonists, stabilizing receptors in their inactive state
D. Enzyme inducers that accelerate histamine breakdown
Correct Answer: C — Inverse agonists, stabilizing receptors in their inactive state
Rationale: Many first-generation antihistamines are inverse agonists at H1 receptors,
actively suppressing constitutive receptor activity. Agonist and partial agonist labels
reverse the effect, and enzyme induction is unrelated.
Question 7. Potency and efficacy differ in that potency refers to:
A. The maximum effect achievable, while potency refers to side effect frequency
B. The speed of absorption only
C. The cost of the medication per prescription
D. The dose needed to produce a given effect, while efficacy refers to the maximum
achievable effect
Correct Answer: D — The dose needed to produce a given effect, while efficacy
refers to the maximum achievable effect
Rationale: Potency is measured by dose requirements such as ED50, while efficacy is
the ceiling of achievable response. Side effects, absorption speed, and cost describe
neither concept.
Question 8. A drug with a narrow therapeutic index, such as lithium, requires:
A. No monitoring because adverse effects are impossible
B. Serum level monitoring because small dosing changes can move the client from
ineffective to toxic
C. Dosing solely by body weight with no laboratory follow-up
D. Stopping the drug whenever the client feels well
Correct Answer: B — Serum level monitoring because small dosing changes can
move the client from ineffective to toxic
Rationale: Narrow therapeutic indices leave little margin between therapeutic and
toxic concentrations, mandating serum surveillance for lithium, valproate, and
carbamazepine. Absence of monitoring and symptom-based discontinuation invite
toxicity.
Question 9. Which property most enables a psychotropic drug to cross the blood-brain
barrier?
A. Large molecular weight with strong protein binding
B. High lipophilicity
C. Highly ionized water-soluble structure
D. Exclusive binding to plasma albumin
Comprehensive Assessment
2026-2027 | Total Questions: 100 | 100% VERIFIED
Introduction
This comprehensive assessment measures the core knowledge required of advanced
nursing nursing candidates preparing for the NR546 Psychopharmacology final
examination. The assessment spans nine domains: Psychopharmacokinetics and
Pharmacodynamics; Neurotransmitter Systems and Receptor Targets; Antidepressant
Therapies; Antipsychotic Medications and Metabolic Monitoring; Anxiolytics and Hypnotics;
Mood Stabilizers; Psychostimulants and ADHD Management; Substance Use Disorder
Pharmacotherapy; and Special Populations. Each question tests a distinct sub-topic mapped
to the official NR546 blueprint, requiring applied professional judgment, receptor-level
reasoning, and safe prescribing decisions rather than simple recall. Mastery of this material
demonstrates readiness for academic progression and supports safe, evidence-based
advanced psychiatric nursing clinical execution.
Question 1. A psychiatric medication undergoes extensive first-pass metabolism. The
clinical consequence is that:
A. The drug bypasses the liver entirely when taken orally
B. Only a fraction of the oral dose reaches systemic circulation, often requiring higher
oral than parenteral doses
C. All of the dose reaches the bloodstream unchanged after oral administration
D. The drug must always be given rectally to work
Correct Answer: B — Only a fraction of the oral dose reaches systemic circulation,
often requiring higher oral than parenteral doses
Rationale: Portal circulation delivers oral drugs directly to hepatic enzymes, so first-
pass metabolism degrades a portion before it reaches the blood, raising oral dose
requirements. The drug does not bypass the liver orally, full bioavailability is false, and
rectal dosing is not a general rule.
Question 2. A client takes a new antidepressant with a half-life of 30 hours. Approximately
how long until steady-state plasma levels are reached?
A. About 5 to 7 days, since steady state requires roughly five half-lives
B. About 60 hours, since two half-lives suffice
C. About 30 minutes after the first dose
D. About 3 months regardless of half-life
Correct Answer: A — About 5 to 7 days, since steady state requires roughly five
half-lives
, Rationale: Steady state is achieved after approximately five half-lives, so five times 30
hours equals 150 hours, about six days. Two half-lives, minutes, and months all
misapply the steady-state rule.
Question 3. A client who smokes two packs daily takes a medication metabolized by
CYP1A2. After smoking cessation, the nurse anticipates that:
A. Plasma levels will rise as the loss of CYP1A2 induction slows metabolism, requiring
dose reduction
B. Plasma levels will fall because smoking protects the drug
C. No change in levels occurs since smoking affects only the lungs
D. The drug must be switched to a parenteral form immediately
Correct Answer: A — Plasma levels will rise as the loss of CYP1A2 induction slows
metabolism, requiring dose reduction
Rationale: Polycyclic aromatic hydrocarbons in smoke induce CYP1A2; cessation
removes the induction, slowing clearance and raising levels of drugs such as olanzapine,
clozapine, and theophylline. Smoking does not lower or ignore drug levels, and the route
is irrelevant.
Question 4. A client with CYP2D6 poor metabolizer genotype takes nortriptyline and
develops marked side effects at a standard dose. The best explanation is:
A. The client has developed a sudden allergy to the medication
B. Poor metabolizers clear drugs faster than extensive metabolizers
C. Genotype has no influence on medication response
D. Reduced enzyme activity slows clearance, so the drug and active metabolites
accumulate
Correct Answer: D — Reduced enzyme activity slows clearance, so the drug and
active metabolites accumulate
Rationale: CYP2D6 poor metabolizers lack efficient enzyme function, so tricyclics and
many psychotropics accumulate, raising toxicity risk at standard doses. Allergy, faster
clearance, and genotype irrelevance are incorrect.
Question 5. A full agonist at a receptor is best described as a drug that:
A. Binds the receptor and produces the maximal possible intrinsic response
B. Binds the receptor and produces a submaximal response even at full occupancy
C. Binds the receptor and blocks endogenous neurotransmitter action completely
D. Binds nowhere and has no receptor activity
Correct Answer: A — Binds the receptor and produces the maximal possible
intrinsic response
Rationale: Full agonists produce maximal signal transduction upon binding. Partial
agonists give a submaximal ceiling, antagonists block rather than activate, and receptor-
less drugs describe nothing.
, Question 6. Classic antihistamines such as diphenhydramine act at the histamine receptor
as:
A. Full agonists, maximally stimulating histamine receptors
B. Partial agonists with ceiling effects
C. Inverse agonists, stabilizing receptors in their inactive state
D. Enzyme inducers that accelerate histamine breakdown
Correct Answer: C — Inverse agonists, stabilizing receptors in their inactive state
Rationale: Many first-generation antihistamines are inverse agonists at H1 receptors,
actively suppressing constitutive receptor activity. Agonist and partial agonist labels
reverse the effect, and enzyme induction is unrelated.
Question 7. Potency and efficacy differ in that potency refers to:
A. The maximum effect achievable, while potency refers to side effect frequency
B. The speed of absorption only
C. The cost of the medication per prescription
D. The dose needed to produce a given effect, while efficacy refers to the maximum
achievable effect
Correct Answer: D — The dose needed to produce a given effect, while efficacy
refers to the maximum achievable effect
Rationale: Potency is measured by dose requirements such as ED50, while efficacy is
the ceiling of achievable response. Side effects, absorption speed, and cost describe
neither concept.
Question 8. A drug with a narrow therapeutic index, such as lithium, requires:
A. No monitoring because adverse effects are impossible
B. Serum level monitoring because small dosing changes can move the client from
ineffective to toxic
C. Dosing solely by body weight with no laboratory follow-up
D. Stopping the drug whenever the client feels well
Correct Answer: B — Serum level monitoring because small dosing changes can
move the client from ineffective to toxic
Rationale: Narrow therapeutic indices leave little margin between therapeutic and
toxic concentrations, mandating serum surveillance for lithium, valproate, and
carbamazepine. Absence of monitoring and symptom-based discontinuation invite
toxicity.
Question 9. Which property most enables a psychotropic drug to cross the blood-brain
barrier?
A. Large molecular weight with strong protein binding
B. High lipophilicity
C. Highly ionized water-soluble structure
D. Exclusive binding to plasma albumin
